• FDA
    Comprehensive Ophthalmology

    RXQ Compounding, LLC is voluntarily recalling sterile human and animal products within expiry, including repackaged bevacizumab (Avastin).

    The nationwide recall, issued on June 18, is due to the lack of sterility process assurance. While all lots of unexpired products produced in Athens, Ohio location are being recalled, RXQ products were distributed nationwide. The company has halted sterile production at their current location while they transition to a new facility.

    Click here for a full list of recalled RXQ Products.

    RQX is notifying customers of the voluntary recall by letter. Customers who have any of the affected medications should immediately discontinue use. Questions should be directed to RXQ Compounding at 740-331-4202 between 9:00 a.m. and 5:00 p.m. ET or via e-mail at Brian.Post@RXQCompounding.com. Consumers should notify physicians or healthcare providers of issues related to recalled drug products.

    To date, RXQ Compounding has not received any reports of adverse events related to the products. Physicians and patients can report adverse reactions or quality issues to the FDA through the MedWatch Adverse Event Reporting site or by mail or fax (1-800-FDA-0178).